Allogene Therapeutics (ALLO) Non-Current Assets (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Non-Current Assets data on file, last reported at $122.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 43.32% year-over-year to $122.7 million; the trailing twelve-month figure through Mar 2026 stood at $647.8 million (down 30.8% YoY), and the FY2025 full-year result was $158.2 million, down 35.53% from the prior year.
• Non-Current Assets declined to $122.7 million in Q1 2026, from $158.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $508.3 million in Q1 2022 to a low of $122.7 million in Q1 2026.
• A 5-year average of $253.4 million and a median of $240.0 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets tumbled 49.48% in 2022 and jumped 33.53% in 2024, its largest moves.
• Tracing ALLO's Non-Current Assets over 5 years: stood at $292.8 million in 2022, then slumped by 37.24% to $183.7 million in 2023, then surged by 33.53% to $245.3 million in 2024, then tumbled by 35.53% to $158.2 million in 2025, then dropped by 22.44% to $122.7 million in 2026.
• Business Quant data shows ALLO's Non-Current Assets at $122.7 million in Q1 2026, $158.2 million in Q4 2025, and $179.1 million in Q3 2025.